Top Story

Pegylated interferon alfa-2b provides minimal benefit as maintenance therapy for osteosarcoma

June 25, 2015

The addition of pegylated interferon alfa-2b maintenance therapy to chemotherapy with methotrexate, doxorubicin and cisplatin did not statistically improves EFS in patients with osteosarcoma, according to the results of a phase 3 study.

Further, a large number of patients reported never starting or prematurely ceasing treatment with pegylated interferon alfa-2b, the researchers also reported.

Emily L. Mueller, MD Meeting News Coverage

Pediatric soft tissue sarcoma survivors at risk for chronic medical conditions

June 16, 2015
CHICAGO — Long-term survivors of pediatric soft tissue sarcoma were at a nearly fourfold higher risk for chronic medical conditions compared with their siblings…
Drug PipelinePerspectivePublication Exclusive

2015 Oncology Drugs in the Pipeline

HemOnc Today, May 25, 2015
HemOnc Today’s annual Oncology Drugs in the Pipeline chart lists agents in phase 2 or phase 3 development for a variety of indications. Clinicians can use this chart as…
Perspective

Eribulin improves survival for patients with advanced liposarcoma, leiomyosarcoma

May 31, 2015
 CHICAGO – The chemotherapy drug eribulin conferred a 2-month median OS improvement in previously treated patients with advanced intermediate or high grade…
CME CNE
High Risk AAMDS

Treatment Decision-Making through the Spectrum of MDS:
Case 2 High Risk MDS

An educational presentation from Aplastic Anemia & MDS International Foundation.

MDS is a difficult disease to diagnose and treat. Frequently it is challenging for healthcare providers to explain to…
More »
CME
Hematology Oncology Case Consults

The Patient with Melanoma

No commercial support for this activity.

This CME activity will focus on the diagnosis and management of patients with melanoma.
More »
In the Journals

Pegylated interferon alfa-2b provides minimal benefit as maintenance therapy for osteosarcoma

June 25, 2015
The addition of pegylated interferon alfa-2b maintenance therapy to chemotherapy with methotrexate, doxorubicin and cisplatin did not statistically…
Emily L. Mueller, MD Meeting News Coverage

Pediatric soft tissue sarcoma survivors at risk for chronic medical conditions

June 16, 2015
CHICAGO — Long-term survivors of pediatric soft tissue sarcoma were at a nearly fourfold higher risk for chronic medical conditions compared…
Drug PipelinePerspectivePublication Exclusive

2015 Oncology Drugs in the Pipeline

HemOnc Today, May 25, 2015
HemOnc Today’s annual Oncology Drugs in the Pipeline chart lists agents in phase 2 or phase 3 development for a variety of indications. Clinicians…
Perspective

Eribulin improves survival for patients with advanced liposarcoma, leiomyosarcoma

May 31, 2015
 CHICAGO – The chemotherapy drug eribulin conferred a 2-month median OS improvement in previously treated patients with advanced…
FDA News

FDA grants orphan drug designation to Triolimus for angiosarcoma

April 29, 2015
The FDA granted orphan drug designation to Triolimus for the treatment of patients with angiosarcoma, according to a press release from the…
In the Journals

Long-term treatment with trabectedin extends PFS, OS in soft tissue sarcoma

March 13, 2015
Patients with soft tissue sarcoma who received trabectedin until disease progression demonstrated significantly improved PFS and OS compared with…
In the Journals

Targeted preoperative radiation reduces late toxicities in extremity sarcoma

March 4, 2015
The use of preoperative image-guided radiation therapy was associated with a reduction in late toxicities among patients with extremity soft tissue…
thumbnail for video 4083320513001 Meeting News CoverageVideo

Video: Highlights in cancer and HIV treatments at CROI 2015

February 27, 2015
Infectious Disease News Chief Medical Editor Paul Volberding, MD, reviews HIV and cancer treatment data presented here at CROI 2015. Highlights…
In the Journals

Boosted PIs lower Kaposi sarcoma incidence

February 10, 2015
Recent data suggest longer duration of treatment with protease inhibitors boosted with Norvir was associated with a reduced incidence of Kaposi…
Maintaining public awareness is critical to solving the problem of drug shortages, according to J. Leonard Lichtenfeld, MD, MACP, deputy chief medical officer for the American Cancer Society. “If we don’t constantly revisit this and make people aware of it, then this will become the status quo,” he said. Cover StoryPublication Exclusive

Expectation of drug shortages has become ‘new norm’ for cancer care

HemOnc Today, February 10, 2015
More than 230 drugs appeared on the American Society of Health-System Pharmacists’ drug shortage list as of mid-January.The list — primarily…
More Headlines »
morganatic-roan